Prostate CancerNCT01858688
A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
A study testing Multiparametric MRI and Prostate biopsy in people with Prostate Cancer, run by Dana-Farber Cancer Institute at 2 sites in United States.
Trial summary
Some men newly diagnosed with prostate cancer do not require immediate treatment. Rather, they can be followed closely with regular physical exams, blood work and repeated biopsies of the prostate. If the prostate cancer is becoming more aggressive, curative treatment can be offered at that time. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Multiparametric MRI and Prostate biopsy
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 101 participants
- Where
- 2 sitesUnited States
- Study dates
- Sep 2013to Apr 2023
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must meet the following criteria on screening examination to be eligible to participate in the study:
- The subject will have histologically confirmed prostate cancer with all of the following features:
- Minimum 10 core prostate biopsy showing histologically-confirmed prostate cancer within 12 months of enrollment reviewed by a pathologist from one of the DF/HCC associated hospitals
- Gleason ≤3+3
- No tertiary Gleason grade ≥4
- ≤3 total cores positive
Show all 15Show fewer
- ≤50% of any given core involved with cancer
- No evidence on biopsy of extracapsular extension
- PSA within one month of enrollment: <10 ng/mL
- Clinical stage: ≤T2a \& N0 or NX \& M0
- The subject is able and willing to abide by the study protocol or cooperate fully with the investigator or designee
- The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document
- Age ≥18
- Life expectancy of greater than 10 years
- Ability to understand and the willingness to sign a written informed consent document.
Who cannot join
- Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.
- First diagnosis of prostate cancer > 12 months prior to enrollment
- Prior prostate cancer-directed therapy including:
- androgen deprivation therapy
- radiation therapy to the prostate (external beam or brachytherapy)
- cryotherapy
Show all 13Show fewer
- high-intensity focused ultrasound (HIFU)
- chemotherapy for prostate cancer
- Prior transurethral resection of prostate
- Subject who is deemed by the treating physician to have a contraindication to definitive treatment
- Subjects with a contraindication to an MRI including those with a pacemaker, ferromagnetic aneurysm clip, or cochlear implants
- Subjects with a contraindication to receiving Gadolinium containing contrast for the MRI
- Conditions which make repeat TRUS biopsies not feasible
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Brigham and Women's Hospital
Boston, Massachusetts, 02215
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
About this study
Some men newly diagnosed with prostate cancer do not require immediate treatment. Rather, they can be followed closely with regular physical exams, blood work and repeated biopsies of the prostate. If the prostate cancer is becoming more aggressive, curative treatment can be offered at that time. This strategy of delaying treatment until necessary is called active surveillance in prostate cancer.
Active surveillance is a way of monitoring prostate cancer which aims to avoid or delay unnecessary treatment in men with less aggressive cancer.
Read more
Prostate cancer can be slow growing and, for many men, the disease may never progress or cause any symptoms. In other words, many men with prostate cancer will never need any treatment. Treatments for prostate cancer may cause side effects which can affect your quality of life. By monitoring the cancer with regular tests, you can avoid or delay these side effects.
Active surveillance is generally suitable for men with low risk early stage prostate cancer that is contained within the prostate gland (localized prostate cancer).
If doctors had a better way of identifying who might be best suited for this approach, it would likely become more appealing for more men. In this study, the investigators are looking at how accurate a magnetic resonance imaging (MRI) scan is at identifying high-risk prostate cancer, which might make a man a poor candidate for active surveillance.
To do this, the investigators are collecting data from the MRI scan of men and comparing it to a trans-rectal biopsy performed following the scan. The results of this study will help inform doctors how accurate the MRI is in identifying men who should not be on active surveillance.
Read the detailed description
Before the research starts (screening): After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated.
- A medical history, which includes questions about your health, current medications, any allergies and evaluation for whether you can safely have an MRI and biopsy
- Performance status, which evaluates how you are able to carry on with your usual activities.
- Review of the initial diagnostic biopsy, which you had when you were diagnosed with prostate cancer.
- Routine Blood Tests ( PSA is a protein that is produced by the prostate gland. The PSA test has been widely used to screen men for prostate cancer. It is also used to monitor men who have been diagnosed with prostate cancer to see if their cancer is responding to therapy)
- Physical Exam
- Health State Questionnaires
- These questionnaires review: Your feelings about your cancer diagnosis, your satisfaction with the cancer care you received, your health and symptoms over the past four weeks, and your overall urinary function
If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in this research study.
After the screening procedures confirm that you are eligible to participate in the research study:
- You will be scheduled for a MRI between 2 to 14 months after your initial biopsy, which showed prostate cancer, to assess the grade and extent of your prostate cancer since your initial diagnosis.
- You will be scheduled for a repeat prostate biopsy 0-3 months after your MRI is reviewed.
Based on the findings from the MRI, this biopsy will be performed either in the urologist's office with an ultrasound (a medical imaging technique that uses high frequency sound waves and their echoes) or using anesthesia and an MRI to guide where the biopsy is taken within the prostate.
If the MRI does not show anything of concern, you will have another ultrasound-guided biopsy similar to the one you had when you were initially diagnosed with prostate cancer. In this procedure twelve biopsy samples are taken from the prostate. Each biopsy is about the length of a dime and as narrow as a toothpick.
If the MRI has findings which need further evaluation, you will have a guided biopsy. In this procedure, you will have twelve samples taken from the prostate similar to the biopsy you had when you were diagnosed with prostate cancer. Additionally, several biopsies will be taken of the area or areas of concern noted on the MRI. This procedure will require anesthesia, which may be general anesthesia or another type. You will meet with the study physician prior to the biopsy procedure. The type of anesthesia to be used will be decided by the study physician in discussion with you. When undergoing a study in the MRI system, you will lie motionless inside this device Occasionally the machine will produce a loud banging noise, as if it were being pounded from the outside with a hammer. Earplugs are available to reduce this sound level.
While you are in the magnet, under the anesthetic, the investigators will do the biopsy. To do this the investigators will use 2 ways to help us reach the correct part of your prostate, one is a robotic needle holder, which will show us where to put the needle, by lining up the correct place outside on the skin or rectal wall and the study physician will push in the needle with his/her hand. Second the investigators will use a model of the best location(s), taken from images. The biopsy is done with a needle put in through the skin, under your scrotum or through the rectal wall by the doctor.
The entire length of the procedure will be approximately 3 hours. The results of the procedure and biopsy will be communicated by your doctor as soon as they are available. The results will also be shared with the research co-investigators. This will be done by sharing the pathology results for each biopsy as matched with the location/place it came from in your gland. The study doctor will share the results of your biopsy with you at your end of study visit.
Medical Information The investigators will collect your medical information when you come to the Dana-Farber Cancer Institute and link this information to your specimens so that the investigators may better understand how these tests affect how participants do over time. It is important to note the following: all blood, tissue, and data collected from participants will be used for research only and when the research is performed on your samples, the investigators conducting this research will not have access to participant identification information, such as medical record numbers.
End of study visit:
You will have an end of study visit approximately 30 days after your final biopsy is performed. At this visit, the study staff will:
- Review your current PSA lab values
- Review the results of your biopsy and discuss options for future treatment.
- Ask you to complete several "Health- State" questionnaires if you have not already done so
- Review any side effects that you may have experienced as a result of your recent biopsy.
- Conditions
- Prostate Cancer
- Being tested
- Multiparametric MRI, Prostate biopsy
- Keywords
- Prostate Cancer, MRI, Active surveillance in prostate cancer
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multiparametric MRIDevice
an MRI of the prostate will be performed
Prostate biopsyProcedure or surgery
a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
| Study group | Role | What they receive |
|---|---|---|
| Accuracy of multi-parametric MRI relative to prostate biopsy | Experimental | Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS. Receives: Device: Multiparametric MRI; Procedure: Prostate biopsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
MP-erMRI Classification Sensitivity
The classification sensitivity of multiparametric endorectal magnetic resonance imaging (MP-erMRI) when compared to the standard of care procedure (transrectal ultrasound-guided (TRUS) re-biopsy) The sensitivity is equivalent to the proportion of patients who were reclassified by MP- erMRI out of the total number of patients who should have been reclassified (given their TRUS re-biopsy result). In other words, it is the proportion of participants reclassified appropriately by MP- erMRI.
Measured: From baseline biopsy to final biopsy, up to 18 months
MP- erMRI Classification Specificity
The classification specificity of multiparametric endorectal magnetic resonance imaging (MP-erMRI) when compared to the standard of care procedure (transrectal ultrasound-guided (TRUS) re-biopsy) The specificity is equivalent to the proportion of patients who were not reclassified by MP- erMRI out of the total number of patients who should have been not reclassified (given their TRUS re-biopsy result). In other words, it is the proportion of participants not reclassified appropriately by MP- erMRI.
Measured: From baseline biopsy to final biopsy, up to 18 months
Secondary outcomes (7)
Frequency of Reclassification
The frequency of reclassification using MP- erMRI, given in the form of a percentage of participants who have been reclassified.
Measured: From baseline biopsy to final MRI, up to 18 months
Median Change in Illness-Related Uncertainty, Anxiety, and Distress
The median change from baseline in illness-related uncertainty, anxiety, and distress measured by The Mishel Uncertainty in Illness Scale Community Form for Active Surveillance (MUIS-AS). The questionnaire entails 15 parts scored from 0-4 for a total of 0-60. The higher the score, the worse the symptoms of uncertainty, anxiety, and distress.
Measured: From baseline biopsy to final MRI, up to 18 months
Median Change in Service Satisfaction
The median change from baseline in service satisfaction measured by Services Satisfaction Scale - for Cancer Care (SSS-Ca). The questionnaire entails 5 parts scored from 1-7 for a total of 7-35. The higher the score, the more dissatisfied the participant.
Measured: From baseline biopsy to final MRI, up to 18 months
Median Change in Prostate Cancer Symptoms
The median change from baseline in prostate cancer symptoms measured by the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP). The questionnaire entails 15 parts scored from 0-4 for a total of 0-60. The higher the score, the worse the symptoms.
Measured: From baseline biopsy to final MRI, up to 18 months
Median Change in Urinary Symptoms
The median change from baseline in urinary symptoms measured by the American Urological Association Symptoms Index (AUA SI). The questionnaire entails 8 parts. Parts 1-7 are scored 0-5 (for a total scoring range of 0-35) and part 8, a question evaluating psychological effect is scored from 0-6. The higher the score, the worse the participant's symptoms.
Measured: From baseline biopsy to final MRI, up to 18 months
Disease Extent by Classification Status
Disease extent evaluated using established methods and given here by MP- erMRI classification status.
Measured: From baseline biopsy to final biopsy, up to 18 months
Gleason Score by Classification Status
Gleason Score evaluated using established methods and given here by MP- erMRI classification status.
Measured: From baseline biopsy to final biopsy, up to 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 May 2013 (estimated)
- Study startSep 2013
- Primary completionMay 2018
- Study completionApr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by Dana-Farber Cancer InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Evaluation of accuracy of the MRI relative to biopsy
- Masking
- None (open label)
- Enrolment
- 101 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dana-Farber Cancer Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Neil Martin, MD, Dana-Farber Cancer Institute
- Investigators
- Neil E Martin, MD, Principal investigator, Dana-Farber Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01858688
- Sponsor's protocol ID
- 13-056
- Status last verified
- Apr 2023
- First submitted
- 15 May 2013
- Last updated
- 3 May 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
- ClinicalTrials.gov ID
- NCT01858688
- Acronym / sponsor ID
- 13-056
- Conditions
- Prostate Cancer
- Keywords
- Prostate Cancer, MRI, Active surveillance in prostate cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 101 participants (actual)
- Lead sponsor
- Dana-Farber Cancer InstituteUniversity, hospital or other
- Study start
- Sep 2013
- Primary completion
- May 2018 (actual)
- Study completion
- Apr 2023 (actual)
- First posted
- 21 May 2013 (estimated)
- Results
- Posted 18 May 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Some men newly diagnosed with prostate cancer do not require immediate treatment. Rather, they can be followed closely with regular physical exams, blood work and repeated biopsies of the prostate. If the prostate cancer is becoming more aggressive, curative treatment can be offered at that time. This strategy of delaying treatment until necessary is called active surveillance in prostate cancer.
Active surveillance is a way of monitoring prostate cancer which aims to avoid or delay unnecessary treatment in men with less aggressive cancer.
Prostate cancer can be slow growing and, for many men, the disease may never progress or cause any symptoms. In other words, many men with prostate cancer will never need any treatment. Treatments for prostate cancer may cause side effects which can affect your quality of life. By monitoring the cancer with regular tests, you can avoid or delay these side effects.
Active surveillance is generally suitable for men with low risk early stage prostate cancer that is contained within the prostate gland (localized prostate cancer).
If doctors had a better way of identifying who might be best suited for this approach, it would likely become more appealing for more men. In this study, the investigators are looking at how accurate a magnetic resonance imaging (MRI) scan is at identifying high-risk prostate cancer, which might make a man a poor candidate for active surveillance.
To do this, the investigators are collecting data from the MRI scan of men and comparing it to a trans-rectal biopsy performed following the scan. The results of this study will help inform doctors how accurate the MRI is in identifying men who should not be on active surveillance.
Detailed description
Before the research starts (screening): After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated.
- A medical history, which includes questions about your health, current medications, any allergies and evaluation for whether you can safely have an MRI and biopsy
- Performance status, which evaluates how you are able to carry on with your usual activities.
- Review of the initial diagnostic biopsy, which you had when you were diagnosed with prostate cancer.
- Routine Blood Tests ( PSA is a protein that is produced by the prostate gland. The PSA test has been widely used to screen men for prostate cancer. It is also used to monitor men who have been diagnosed with prostate cancer to see if their cancer is responding to therapy)
- Physical Exam
- Health State Questionnaires
- These questionnaires review: Your feelings about your cancer diagnosis, your satisfaction with the cancer care you received, your health and symptoms over the past four weeks, and your overall urinary function
If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in this research study.
After the screening procedures confirm that you are eligible to participate in the research study:
- You will be scheduled for a MRI between 2 to 14 months after your initial biopsy, which showed prostate cancer, to assess the grade and extent of your prostate cancer since your initial diagnosis.
- You will be scheduled for a repeat prostate biopsy 0-3 months after your MRI is reviewed.
Based on the findings from the MRI, this biopsy will be performed either in the urologist's office with an ultrasound (a medical imaging technique that uses high frequency sound waves and their echoes) or using anesthesia and an MRI to guide where the biopsy is taken within the prostate.
If the MRI does not show anything of concern, you will have another ultrasound-guided biopsy similar to the one you had when you were initially diagnosed with prostate cancer. In this procedure twelve biopsy samples are taken from the prostate. Each biopsy is about the length of a dime and as narrow as a toothpick.
If the MRI has findings which need further evaluation, you will have a guided biopsy. In this procedure, you will have twelve samples taken from the prostate similar to the biopsy you had when you were diagnosed with prostate cancer. Additionally, several biopsies will be taken of the area or areas of concern noted on the MRI. This procedure will require anesthesia, which may be general anesthesia or another type. You will meet with the study physician prior to the biopsy procedure. The type of anesthesia to be used will be decided by the study physician in discussion with you. When undergoing a study in the MRI system, you will lie motionless inside this device Occasionally the machine will produce a loud banging noise, as if it were being pounded from the outside with a hammer. Earplugs are available to reduce this sound level.
While you are in the magnet, under the anesthetic, the investigators will do the biopsy. To do this the investigators will use 2 ways to help us reach the correct part of your prostate, one is a robotic needle holder, which will show us where to put the needle, by lining up the correct place outside on the skin or rectal wall and the study physician will push in the needle with his/her hand. Second the investigators will use a model of the best location(s), taken from images. The biopsy is done with a needle put in through the skin, under your scrotum or through the rectal wall by the doctor.
The entire length of the procedure will be approximately 3 hours. The results of the procedure and biopsy will be communicated by your doctor as soon as they are available. The results will also be shared with the research co-investigators. This will be done by sharing the pathology results for each biopsy as matched with the location/place it came from in your gland. The study doctor will share the results of your biopsy with you at your end of study visit.
Medical Information The investigators will collect your medical information when you come to the Dana-Farber Cancer Institute and link this information to your specimens so that the investigators may better understand how these tests affect how participants do over time. It is important to note the following: all blood, tissue, and data collected from participants will be used for research only and when the research is performed on your samples, the investigators conducting this research will not have access to participant identification information, such as medical record numbers.
End of study visit:
You will have an end of study visit approximately 30 days after your final biopsy is performed. At this visit, the study staff will:
- Review your current PSA lab values
- Review the results of your biopsy and discuss options for future treatment.
- Ask you to complete several "Health- State" questionnaires if you have not already done so
- Review any side effects that you may have experienced as a result of your recent biopsy.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Evaluation of accuracy of the MRI relative to biopsy
| Arm | Type | Receives |
|---|---|---|
| Accuracy of multi-parametric MRI relative to prostate biopsy | Experimental | Device: Multiparametric MRI, Procedure: Prostate biopsyDetermine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Participants must meet the following criteria on screening examination to be eligible to participate in the study:
- The subject will have histologically confirmed prostate cancer with all of the following features:
- Minimum 10 core prostate biopsy showing histologically-confirmed prostate cancer within 12 months of enrollment reviewed by a pathologist from one of the DF/HCC associated hospitals
- Gleason ≤3+3
- No tertiary Gleason grade ≥4
Key exclusion criteria (13 listed)
- Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.
- First diagnosis of prostate cancer > 12 months prior to enrollment
- Prior prostate cancer-directed therapy including:
- androgen deprivation therapy
- radiation therapy to the prostate (external beam or brachytherapy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multiparametric MRIan MRI of the prostate will be performed | Device | Accuracy of multi-parametric MRI relative to prostate biopsy |
| Prostate biopsya biopsy of the prostate will be performed according to standard procedures for men on active surveillance | Procedure or surgery | Accuracy of multi-parametric MRI relative to prostate biopsy |
Primary outcome
MP-erMRI Classification Sensitivity
Time frame: From baseline biopsy to final biopsy, up to 18 months
The classification sensitivity of multiparametric endorectal magnetic resonance imaging (MP-erMRI) when compared to the standard of care procedure (transrectal ultrasound-guided (TRUS) re-biopsy) The sensitivity is equivalent to the proportion of patients who were reclassified by MP- erMRI out of the total number of patients who should have been reclassified (given their TRUS re-biopsy result). In other words, it is the proportion of participants reclassified appropriately by MP- erMRI.
MP- erMRI Classification Specificity
Time frame: From baseline biopsy to final biopsy, up to 18 months
The classification specificity of multiparametric endorectal magnetic resonance imaging (MP-erMRI) when compared to the standard of care procedure (transrectal ultrasound-guided (TRUS) re-biopsy) The specificity is equivalent to the proportion of patients who were not reclassified by MP- erMRI out of the total number of patients who should have been not reclassified (given their TRUS re-biopsy result). In other words, it is the proportion of participants not reclassified appropriately by MP- erMRI.
7 secondary outcomes
Frequency of Reclassification
Time frame: From baseline biopsy to final MRI, up to 18 months
Median Change in Illness-Related Uncertainty, Anxiety, and Distress
Time frame: From baseline biopsy to final MRI, up to 18 months
Median Change in Service Satisfaction
Time frame: From baseline biopsy to final MRI, up to 18 months
Median Change in Prostate Cancer Symptoms
Time frame: From baseline biopsy to final MRI, up to 18 months
Median Change in Urinary Symptoms
Time frame: From baseline biopsy to final MRI, up to 18 months
Disease Extent by Classification Status
Time frame: From baseline biopsy to final biopsy, up to 18 months
Gleason Score by Classification Status
Time frame: From baseline biopsy to final biopsy, up to 18 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Neil E Martin, MD principal investigator
Dana-Farber Cancer Institute
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multiparametric MRI and Prostate biopsy in people with Prostate Cancer, run by Dana-Farber Cancer Institute at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 18 May 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MP-erMRI Classification Sensitivity (time frame: From baseline biopsy to final biopsy, up to 18 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2023.